Nurix Therapeutics Announces Clearance of Investigational New Drug Application for NX-5948…
NX-5948 is being evaluated in patients with relapsed and refractory B-cell malignancies Phase 1 clinical trial now enrolling patients in the United Kingdom with plans to expand to clinical sites in the United States SAN FRANCISCO, Dec.…